RNA Q3 2025 Earnings — Avidity Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RNAAvidity Biosciences, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+434.0% YoY

Gross Profit

$12M100.0% margin

Operating Income

-$189M-1513.5% margin

Net Income

-$174M-1398.3% margin

EPS (Diluted)

$-1.27

QoQ Revenue Growth

+224.3%

Cash Flow

Operating Cash Flow

-$156M

Free Cash Flow

-$160M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$248M

Stockholders' Equity

$1.9B

Cash & Equivalents

$350M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$2M	+434.0%
Gross Profit	$12M	$2M	+434.0%
Operating Income	-$189M	-$98M	-92.4%
Net Income	-$174M	-$80M	-117.0%

Revenue Segments

Reportable Segment

$12M100%